Loading...
TNXP TONIX PHARMACEUTICALS HOLDING CORP Expansion Plans 8-K Filing
Back
TNX
TNXP
TONIX PHARMACEUTICALS HOLDING CORP
(TNXP)
Follow
FY2024 8 K
View More
Back
TNX
TNXP
TONIX PHARMACEUTICALS HOLDING CORP
(TNXP)
Follow
FY2024 8 K
Filing:
8 K
Published on:
4 Nov '24
Product Expansion
24 Apr '25
Research Collaboration
9 Apr '25
Product Launch
1 Apr '25
FDA Update
24 Mar '25
Earnings Report
18 Mar '25
Grant Award
10 Mar '25
Management Change
4 Mar '25
Conference Presentation
4 Mar '25
NASDAQ Compliance
21 Feb '25
Financial Update
7 Feb '25
Positive Trial Results
6 Feb '25
Management Change
4 Feb '25
Loan Termination & Split
3 Feb '25
Management Change
8 Jan '25
FDA Approval Date
23 Dec '24
Share Offering Increase
20 Dec '24
FDA Application Accepted
17 Dec '24
Management Changes
3 Dec '24
Leadership Expansion
3 Dec '24
Vaccine Data Release
13 Nov '24
Quarterly Results
12 Nov '24
Product Update
8 Nov '24
Research Partnership
4 Nov '24
Vaccine Presentation
1 Nov '24
Shareholder Meeting
30 Oct '24
Q3 2024 Results
28 Oct '24
Funding Announcement
17 Oct '24
FDA Application
16 Oct '24
AI Collaboration
8 Oct '24
Patent Issuance
27 Sep '24
Product Presentation
23 Sep '24
Patent Issued
19 Sep '24
Vaccine Alignment
16 Sep '24
Management Change
10 Sep '24
Vaccine Presentation
9 Sep '24
Share Repurchase
6 Sep '24
Share Offering Increase
30 Aug '24
Vaccine Collaboration
26 Aug '24
Clinical Trial Update
20 Aug '24
Quarterly Results
19 Aug '24
Trial Results
12 Aug '24
Results of Operations and F...
9 Aug '24
Sales Agreement
30 Jul '24
FDA Fast Track Designation ...
25 Jul '24
Decommissioning of Facility
24 Jul '24
Update
16 Jul '24
Agreement for Public Offering
10 Jul '24
FDA Meeting for Tonmya NDA
8 Jul '24
Agreement with Defense Thre...
1 Jul '24
8-K Filing
28 Jun '24
Compliance with NASDAQ List...
26 Jun '24
FDA Meeting for Tonmya Prod...
20 Jun '24
Amendment to Filing
14 Jun '24
Agreement for Public Offering
13 Jun '24
Update
10 Jun '24
Reverse Stock Split
6 Jun '24
Data Announcement
6 Jun '24
Data from Phase 3 RESILIENT...
3 Jun '24
Data Announcement
30 May '24
Workforce Reduction and Dec...
22 May '24
ASCP Annual Meeting Present...
22 May '24
Market Assessment Results
21 May '24
Earnings Reports
13 May '24
Earnings Report
1 Apr '24
Securities Purchase Agreement
29 Mar '24
FDA Designation for TNX-290...
25 Mar '24
Poster Presentation at ACS ...
21 Mar '24
Selection of Contract Manuf...
20 Mar '24
Quantitative Data
19 Mar '24
Additional Efficacy Data An...
11 Mar '24
Publication of Research Paper
7 Mar '24
Investment Support for Tonm...
6 Mar '24
Announcement of TNX-1500 Ph...
5 Mar '24
Product Trial Completion
28 Feb '24
Clinical Study Results
27 Feb '24
Shareholder Approval
15 Feb '24
Engagement of Rho for NDA s...
13 Feb '24
FDA Clearance for OASIS Trial
12 Feb '24
Research Findings on Long C...
31 Jan '24
FDA Acceptance of Trade Name
29 Jan '24
Amendment to Articles of In...
25 Jan '24
Workforce Reduction
19 Jan '24
Additional Data Announcement
8 Jan '24
Update & FDA Decision
2 Jan '24
Securities Purchase Agreement
21 Dec '23
Positive Clinical Trial Res...
20 Dec '23
Update
12 Dec '23
Loan Agreement
8 Dec '23
FDA Clearance for TNX-2900 ...
4 Dec '23
Enrollment in Phase 2 study...
13 Nov '23
Earnings Report
9 Nov '23
Clinical Trial with TNX-180...
2 Nov '23
Discontinuation of TNX-601 ...
31 Oct '23
Data from oral presentation...
30 Oct '23
Product Launch
26 Oct '23
Notice from Nasdaq
20 Oct '23
Presentation at World Vacci...
19 Oct '23
Product Launch
18 Oct '23
Update
16 Oct '23
Clinical Phase Completion
16 Oct '23
External Links:
SEC
AI Assistant
Close
TONIX PHARMACEUTICALS HOLDING CORP
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.